Evidence map›Paper›PMID 36344580›Full record

ArticleScientific reports2022

Machine learning based personalized drug response prediction for lung cancer patients.

Rizwan Qureshi, Syed Abdullah Basit, Jawwad A Shamsi, Xinqi Fan, Mehmood Nawaz, Hong Yan, Tanvir Alam

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Rizwan QureshiCollege of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar.
Syed Abdullah BasitFAST National University of Computer and Emerging Sciences, Karachi, Pakistan.
Jawwad A ShamsiFAST National University of Computer and Emerging Sciences, Karachi, Pakistan.
Xinqi FanDepartment of Electrical Engineering, City University of Hong Kong, Kowloon, Hong Kong.
Mehmood NawazDepartment of Biomedical Engineering, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China.
Hong YanDepartment of Electrical Engineering, City University of Hong Kong, Kowloon, Hong Kong.
Tanvir AlamCollege of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar. talam@hbku.edu.qa.
City University of Hong Kong · HKHamad bin Khalifa University · QANational University of Computer and Emerging Sciences · PKChinese University of Hong Kong · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been developed against EGFR and show encouraging results for survival rate and quality of life. However, drug resistance may affect treatment plans and treatment efficacy may be lost after about a year. Predicting the response to EGFR-TKIs for EGFR-mutated lung cancer patients is a key research area. In this study, we propose a personalized drug response prediction model (PDRP), based on molecular dynamics simulations and machine learning, to predict the response of first generation FDA-approved small molecule EGFR-TKIs, Gefitinib/Erlotinib, in lung cancer patients. The patient's mutation status is taken into consideration in molecular dynamics (MD) simulation. Each patient's unique mutation status was modeled considering MD simulation to extract molecular-level geometric features. Moreover, additional clinical features were incorporated into machine learning model for drug response prediction. The complete feature set includes demographic and clinical information (DCI), geometrical properties of the drug-target binding site, and the binding free energy of the drug-target complex from the MD simulation. PDRP incorporates an XGBoost classifier, which achieves state-of-the-art performance with 97.5% accuracy, 93% recall, 96.5% precision, and 94% F1-score, for a 4-class drug response prediction task. We found that modeling the geometry of the binding pocket combined with binding free energy is a good predictor for drug response. However, we observed that clinical information had a little impact on the performance of the model. The proposed model could be tested on other types of cancers. We believe PDRP will support the planning of effective treatment regimes based on clinical-genomic information. The source code and related files are available on GitHub at:   https://github.com/rizwanqureshi123/PDRP/ .

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsHumansMachine LearningMutationProtein Kinase InhibitorsQuality of LifeErbB ReceptorsProtein Kinase Inhibitors

Identifiers

PMID36344580
PMCPMC9640729
OpenAlexW4308769931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.